ABCC transporter inhibition reduces zymosan-induced peritonitis

Leite, Daniela Ferraz Pereira; Echevarria-Lima, Juliana; Ferreira, Samira Cardoso; Calixto, João B.; Rumjanek, Vivian M.

doi:10.1189/jlb.0107042

Cited by 23 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The volume of plasma leakage (ll) for 30 min after zymosan A i.p. injection was calculated by dividing the amount of Evans blue dye in the peritoneal lavage fluid (lg) by the concentration of Evans blue dye in the serum (lg/ll) [31].…”

Section: Effect Of Polyunsaturated Lysoptdcho On Zymosan A-induced Pementioning

confidence: 99%

See 1 more Smart Citation

Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn‐1 Position is Anti‐inflammatory

Huang

Nguyen

Sok

et al. 2010

Lipids

View full text Add to dashboard Cite

Lysophosphatidylcholine is known to be a lipid mediator in various cellular responses. In this study, we examined the anti-inflammatory actions of lysophosphatidylcholine containing docosahexaenoic acid esterified at the sn-1 position. First, in RAW 264.7 cells, DHA-lysoPtdCho suppressed the LPS-induced formation of NO concentration-dependently. However, ARA-lysoPtdCho showed a partial suppression, and LNA-lysoPtdCho had no significant effect. Additionally, DHA-lysoPtdCho also reduced the level of TNF-alpha or IL-6, but not PGE(2). In animal experiments, the i.v. administration of ARA-lysoPtdCho (150 or 500 mug/kg) prevented zymosan A-induced plasma leakage remarkably with a maximal efficacy (Emax) of 50%, in contrast to no effect with LNA-lysoPtdCho. Remarkably, DHA-lysoPtdCho suppressed zymosan A-induced plasma leakage with an ED(50) value of 46 mug/kg and an Emax value of around 95%. Additionally, mechanistic studies indicated that the anti-inflammatory action of DHA-lysoPtdCho was partially related to the reduced formation of LTC(4,) TNF-alpha, and IL-6. When the interval time between lysoPtdCho administration and zymosan A challenge was extended up to 2 h, such a suppressive action of DHA-lysoPtdCho was augmented, suggesting that a DHA-lysoPtdCho metabolite is important for anti-inflammatory action. In support of this, 17-HPDHA-lysoPtdCho showed a greater anti-inflammatory action than DHA-lysoPtdCho. Furthermore, a similar anti-inflammatory action was also observed with i.p. administration of DHA-lysoPtdCho or a 17(S)-hydroperoxy derivative. Additionally, oral administration of DHA-lysoPtdCho also expressed a significant anti-inflammatory action. Taken together, it is proposed that DHA-lysoPtdCho and its metabolites may be anti-inflammatory lipids in vivo systems.

show abstract

Section: Effect Of Polyunsaturated Lysoptdcho On Zymosan A-induced Pementioning

confidence: 99%

“…administration of zymosan A as described above. Total cell counting were performed for lavage fluid collected at the 90 min time point using light microscopy together with trypan blue staining [31,32].…”

Section: Effect Of Polyunsaturated Lysoptdcho On Zymosan A-induced Pementioning

confidence: 99%

Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn‐1 Position is Anti‐inflammatory

Huang

Nguyen

Sok

et al. 2010

Lipids

View full text Add to dashboard Cite

show abstract

“…administration of zymosan A (1 mg/mouse) as described previously [22][23][24]. For the measurement of plasma leakage, mice were treated orally with 200 ll of each lysoPtdEtn taken from [25,26].…”

Section: Zymosan A-induced Peritonitis In Icr Micementioning

confidence: 99%

2‐Polyunsaturated Acyl Lysophosphatidylethanolamine Attenuates Inflammatory Response in Zymosan A‐Induced Peritonitis in Mice

Nguyen

Kim

Sok

2011

Lipids

View full text Add to dashboard Cite

In the present study, the anti-inflammatory action of lysophosphatidylethanolamine (lysoPtdEtn), orally administered, in zymosan A-induced peritonitis was examined. Oral administration of 2-DHA-lysoPtdEtn (ED(50), ~111 μg/kg) or 2-ARA-lysoPtdEtn (ED(50), 221 μg/kg) was found to inhibit the plasma leakage in mice treated with zymosan A. In support of this, 2-polyunsaturated acyl-lysoPtdEtn diminished the formation of LTC(4), a lipid mediator responsible for vascular permeability. Next, 2-DHA-lysoPtdEtn (ED(50), 110 μg/kg) or 2-ARA-lysoPtdEtn (ED(50), 123 μg/kg) effectively inhibited the leukocyte extravasation into the peritoneum. Consistent with this, each polyunsaturated-lysoPtdEtn diminished the formation of LTB(4) and 12-HETE, potent chemotactic factors. Additionally, the level of pro-inflammatory mediator (IL-1 β, IL-6, TNF-α or NO) was lowered remarkably in contrast to the augmentation of anti-inflammatory interleukin IL-10. Furthermore, 2-(15-HETE)-lysoPtdEtn and 2-(17-HDHE)-lysoPtdEtn, 15-lipoxygenation product of 2-ARA-lysoPtdEtn and 2-DHA-lysoPtdEtn, respectively, were more potent than corresponding lysoPtdEtn, suggesting the action of 2-acyl-lysoPtdEtn might be expressed through 15-lipoxygenation. In support of this, the formation of 15-HETE and LXA(4) was upgraded in accordance with an increasing dose of 2-ARA-lysoPtdEtn. Separately, anti-inflammatory actions, 2-polyunsaturated acyl-lysoPtdEtns also drastically diminished leukocyte infiltration in a later phase of zymosan A-induced peritonitis, indicating that these lipids also possess pro-resolving activity. Taken together, it is suggested that polyunsaturated lysoPtdEtns and their lipoxygenation derivatives, could be classified as potent anti-inflammatory lipids.

show abstract

“…Zymosan induces mastocite degranulation and activates macrophages (Kolaczkowska et al, 2001). When administered in the peritoneal cavity of mice, Zymosan promotes an increase in vascular leakage as one of the first signs of inflammation, followed by a recruitment of migratory cells (Leite et al 2007). In this test, the results demonstrated that the extracts and the chloroformic fraction from E. mulungu significantly reduced the number of recruit cells, indicating that these compounds contain active anti-inflammatory principles.…”

Section: Discussionmentioning

confidence: 50%

Antinociceptive and anti-inflammatory activity of hydroalcoholic extracts and fractions from Erythrina mulungu

Oliveira¹,

Aquino²,

Silva³

et al. 2012

Rev. bras. farmacogn.

View full text Add to dashboard Cite

Erythrina mulungu Mart. ex Benth., Fabaceae, popularly known as mulungu, is used for the treatment of insomnia and disorders of the central nervous system. This study examined the antinociceptive effects of the hydroalcoholic extracts (HAE), the ethyl acetate and chloroformic fractions from E. mulungu in four experimental models of nociception using laboratory mice. The extracts and fractions were administered orally to mice at doses of 100 mg/kg. Inhibition of abdominal contractions were observed for all the extracts and fractions tested, as compared to controls. All extracts and fractions from E. mulungu reduced the nociception activity produced by formalin in the 2 nd phase. In the hot plate test no significant effect was observed for any extract or fraction. In the peritonitis test induced by Zymosan, all of the tested extracts and the chloroformic fraction, except for the ethyl acetate phase, reduced cell migration of the peritoneal cavity. We concluded that E. mulungu shows antinociceptive effects, which are independent of the opioid system.

show abstract

ABCC transporter inhibition reduces zymosan-induced peritonitis

Cited by 23 publications

References 33 publications

Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn‐1 Position is Anti‐inflammatory

Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn‐1 Position is Anti‐inflammatory

2‐Polyunsaturated Acyl Lysophosphatidylethanolamine Attenuates Inflammatory Response in Zymosan A‐Induced Peritonitis in Mice

Antinociceptive and anti-inflammatory activity of hydroalcoholic extracts and fractions from Erythrina mulungu

Contact Info

Product

Resources

About